Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 4/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933193 | 1.00 | LMNA (0.38) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL23462293 | 0.86 | ALDH1A1 (0.38) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL23462292 | 0.86 | ALDH1A1 (0.38) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL23462308 | 0.84 | ALDH1A1 (0.36) | LMNAPOLBALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL23462309 | 0.84 | ALDH1A1 (0.36) | LMNAPOLBALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL20818486 | 0.79 | ALDH1A1 (0.40) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL2896462 | 0.76 | ALDH1A1 (0.48) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL12957073 | 0.74 | ALDH1A1 (0.46) | LMNAPOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL20818558 | 0.73 | ALDH1A1 (0.33) | LMNAPOLBALDH1A1KMT2ANPC1 | |
| SCHEMBL8242935 | 0.71 | ALDH1A1 (0.43) | LMNAPOLBALDH1A1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-4139296-B1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| CN-116323588-A | Compounds and methods for CD73 modulation and indications therefor | 奥普纳生物有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4139296-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Immuno Oncology, SA (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | disclosed |
| WO-2021216898-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | LMNA 1207/4885POLB 1748/4885ALDH1A1 208/4885 |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | LMNA 1207/4885POLB 1748/4885ALDH1A1 208/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | LMNA 1207/4885POLB 1748/4885ALDH1A1 208/4885 |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | LMNA 1218/4885POLB 1741/4885ALDH1A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.